Biomerica, Inc. (BMRA) |
2.875 -0.075 (-2.54%) 10-10 11:56 |
Open: | 2.95 |
High: | 2.95 |
Low: | 2.825 |
Volume: | 17,055 |
Market Cap: | 8(M) |
PE Ratio: | -1.33 |
Exchange: | NASDAQ Capital Market |
Industry: | Medical - Devices |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 3.60 |
Resistance 1: | 3.08 |
Pivot price: | 2.85 |
Support 1: | 2.83 |
Support 2: | 2.68 |
52w High: | 10.16 |
52w Low: | 2.08 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
EPS | -2.160 |
Book Value | 1.610 |
PEG Ratio | 0.00 |
Gross Profit | 0.174 |
Profit Margin (%) | -93.64 |
Operating Margin (%) | -208.81 |
Return on Assets (ttm) | -42.3 |
Return on Equity (ttm) | -93.0 |
Wed, 08 Oct 2025
Gary Huff Joins Biomerica Board as Independent Director — Former LabCorp Diagnostics CEO to Advise Growth - Stock Titan
Fri, 29 Aug 2025
$1.3 Million Cost Reduction Drives 19% Operating Loss Improvement: Biomerica's Strategic Turnaround - Stock Titan
Fri, 29 Aug 2025
Biomerica, Inc. Reports $1.3 Million in Operating Expense Reductions and 19% Improvement in Operating Loss Year-Over-Year | BMRA Stock News - Quiver Quantitative
Thu, 14 Aug 2025
New 10-minute home test detects H. pylori infection linked to 80% of gastric cancers - Stock Titan
Thu, 14 Aug 2025
Biomerica Inc. Rally: What’s Next? - timothysykes.com
Thu, 14 Aug 2025
Biomerica’s Unexpected Surge: Will It Hold Steady? - StocksToTrade
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |